{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-081006","form_type":"8-K","ticker":"ABT","cik":"0000001800","company_name":"ABBOTT LABORATORIES","filed_at":"2022-07-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:57.076913+00:00","generated_at":"2026-06-24T11:33:49.470250+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Abbott Q2 EPS $1.14 GAAP, $1.43 adj; raises FY adj EPS view to $4.90+","bullets":["Q2 sales $11.3B (+10.1% reported, +14.3% organic); GAAP EPS $1.14, adjusted EPS $1.43 (+22.2%).","COVID-19 testing sales $2.3B in Q2; full-year COVID testing revenue projected at $6.1B.","Raised FY 2022 GAAP EPS guidance to at least $3.50, adjusted EPS to at least $4.90.","Nutrition sales down 7.4% reported due to infant formula recall; Adult Nutrition organic growth +5.2%.","Medical Devices organic growth +7.5% driven by Diabetes Care FreeStyle Libre (+25.6% organic)."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-081006","json":"https://secwatch.observer/filing/0001104659-22-081006.json","markdown":"https://secwatch.observer/filing/0001104659-22-081006.md","text":"https://secwatch.observer/filing/0001104659-22-081006.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1800/000110465922081006/0001104659-22-081006-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1800/000110465922081006/tm2221376d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T11:33:49.470250+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}